Associate Prof. Deyarina Gonzalez
Telephone +44 (0)1792 295384
Deya’s research focuses on gene expression and function in the uterus and its relationship to fertility and cancer. Her clinical interests are Polycystic Ovary Syndrome (PCOS), endometriosis, unexplained infertility and gynaecological cancers (endometrial, ovarian and cervical cancer). She has strategic collaborations with clinicians at Abertawe Bro Morgannwg University NHS health board, developing cellular and molecular approaches to determine mechanisms underlying gynaecological pathologies, to identify biomarkers. Her projects on endometrial implantation and differentiation, relate to L-selectin ligands (MUC1), hormone nuclear receptors and WT1 pathway. Her research in gynaecological cancer includes the regulation of tamoxifen target genes in endometrium and new methods to identify biomarkers for pre-disposition of infertile women to develop gynaecological cancers. Her aim is to translate basic research into clinically relevant observations for patient benefit. Her projects involve collaboration with the private sector to expedite validation of clinical diagnostic biomarkers and the development of new drug leads for targeted cancer therapy. She also has multidisciplinary collaborations in the area of nanosensors and improved performance medications in the field of human reproductive biology and hormone therapy. She has received research grants valuing over £1m in the recent years.
Deya has published more than 20 articles during her career on human, animal, plant and yeast research. She is a member of the Endocrine Society and acts as an expert reviewer for Journal of Clinical Endocrinology and Metabolism, Human Reproduction and others. She teaches within the Genetics & Biochemistry (College of Medicine) and Biomedical Engineering (College of Engineering) undergraduate programmes.
About research group
Reproductive biology and gynaecological oncology research in Swansea covers basic and translational research into uterine pathologies including endometrial cancer, poly-cystic ovary syndrome, endometriosis and unexplained infertility linked to endometrial (the lining of the womb) dysfunction. More recently new research has been established in the areas of ovarian cancer, ovarian reserve and overactive bladder syndrome. Our research involves the study of cell signalling, nanobiology, transcription and epigenetics, the development of clinically relevant biomarkers, and the development of therapeutic interventions. Our group works closely with clinicians in the Departments of Obstetrics and Gynaecology, and Pathology, in the Abertawe Bro Morgannwg University Health Board in Singleton Hospital, Swansea, and The Princess of Wales Hospital in Bridgend.
Antibody Drug Conjugates for gynaecological cancers.
Antibody drug conjugates (ADCs) combine the specificity of antibodies with the potency of small molecule cytotoxic drugs. This presentation will give an overview about the current state of ADC development. A novel ADC developed by Swansea University as a potential therapeutic for the treatment of gynaecological cancers will be discussed in more detail and latest results will be presented. The evaluation of ADCs activity using screening platforms will be discussed.
Please click to logos to go back to the agenda
School of Chemistry, Bangor University, Bangor, Gwynedd, LL57 2UW, UK
Direct Line: 0044 1248 383741 email: email@example.com